156 related articles for article (PubMed ID: 38175824)
1. Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials.
Ngongondo M; Ritz J; Hughes MD; Matoga M; Hosseinipour MC;
PLOS Glob Public Health; 2024; 4(1):e0002648. PubMed ID: 38175824
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
[TBL] [Abstract][Full Text] [Related]
3. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and factors associated with renal dysfunction in patients on tenofovir disoproxil fumarate-based antiretroviral regimens for HIV infection in Southern India.
Kumarasamy N; Sundaram S; Poongulali S; Ezhilarasi C; Pradeep A; Chitra D
J Virus Erad; 2018 Jan; 4(1):37-40. PubMed ID: 29568552
[TBL] [Abstract][Full Text] [Related]
6. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Gupta SK; Post FA; Arribas JR; Eron JJ; Wohl DA; Clarke AE; Sax PE; Stellbrink HJ; Esser S; Pozniak AL; Podzamczer D; Waters L; Orkin C; Rockstroh JK; Mudrikova T; Negredo E; Elion RA; Guo S; Zhong L; Carter C; Martin H; Brainard D; SenGupta D; Das M
AIDS; 2019 Jul; 33(9):1455-1465. PubMed ID: 30932951
[TBL] [Abstract][Full Text] [Related]
7. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
Nishijima T; Kurosawa T; Tanaka N; Kawasaki Y; Kikuchi Y; Oka S; Gatanaga H
AIDS; 2016 Jun; 30(10):1563-71. PubMed ID: 26919734
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
Bedimo R; Rosenblatt L; Myers J
HIV Clin Trials; 2016 Nov; 17(6):246-266. PubMed ID: 27809711
[TBL] [Abstract][Full Text] [Related]
9. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
Gallant JE; Winston JA; DeJesus E; Pozniak AL; Chen SS; Cheng AK; Enejosa JV
AIDS; 2008 Oct; 22(16):2155-63. PubMed ID: 18832879
[TBL] [Abstract][Full Text] [Related]
10. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
Decloedt EH; Lesosky M; Maartens G; Joska JA
AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
[TBL] [Abstract][Full Text] [Related]
11. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
[TBL] [Abstract][Full Text] [Related]
12. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
Yilma D; Abdissa A; Kæstel P; Tesfaye M; Olsen MF; Girma T; Ritz C; Friis H; Andersen ÅB; Kirk O
BMC Infect Dis; 2020 Aug; 20(1):582. PubMed ID: 32762646
[TBL] [Abstract][Full Text] [Related]
13. The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort.
Monteiro N; Branco M; Peres S; Borges F; Mansinho K
J Int AIDS Soc; 2014; 17(4 Suppl 3):19565. PubMed ID: 25394072
[TBL] [Abstract][Full Text] [Related]
14. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?
Calcagno A; Fiumanò M; Zugna D; Cusato J; Montrucchio C; Marinaro L; Trentini L; Ferrara M; D'Avolio A; Pizzi C; Di Perri G; Bonora S
Pharmacogenomics J; 2019 Feb; 19(1):65-71. PubMed ID: 30405212
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.
Costarelli S; Cozzi-Lepri A; Lapadula G; Bonora S; Madeddu G; Maggiolo F; Antinori A; Galli M; Di Perri G; Viale P; d'Arminio Monforte A; Gori A;
PLoS One; 2016; 11(10):e0160761. PubMed ID: 27716843
[TBL] [Abstract][Full Text] [Related]
18. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
Cooper RD; Wiebe N; Smith N; Keiser P; Naicker S; Tonelli M
Clin Infect Dis; 2010 Sep; 51(5):496-505. PubMed ID: 20673002
[TBL] [Abstract][Full Text] [Related]
20. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
Judd A; Boyd KL; Stöhr W; Dunn D; Butler K; Lyall H; Sharland M; Shingadia D; Riordan A; Gibb DM
AIDS; 2010 Feb; 24(4):525-34. PubMed ID: 20139752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
